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Spurious correlation in estimation of the health production
function: A note
Abstract
In this paper, we address the issue of spurious correlation in the production of health in a systematic
way. Spurious correlation entails the risk of linking health status to medical (and nonmedical) inputs
when no links exist. This note first presents the bounds testing procedure as a method to detect and
avoid spurious correlation. It then applies it to a recent contribution by Lichtenberg (2004), which
relates longevity in the United States to pharmaceutical innovation and public health care expenditure.
The results of the bounds testing procedure show longevity to be related to these two factors. Therefore,
the estimates reported by Lichtenberg (2004) cannot be said to be result of spurious correlation, to the
contrary, they very likely reflect an effective relationship, at least for the United States.
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1. Introduction 
 
The issue of spurious correlation in models involving time series data has a long history. 
Already in the third decade of the 20th century Yule pointed out on pitfalls of correlation 
analysis applied to trending data (Yule, 1926). The topic received further development in 
Granger and Newbold (1974) and Engle and Granger (1987) where the problem of spurious 
correlation has been formalized and the initial solution has been provided, respectively. In 
particular, it was emphasized that in order to avoid spurious correlation between the time 
series of interest one has to conduct pretesting for the presence of unit roots first and then 
apply cointegration analysis. Failure to do so entails the risk of finding a statistically 
significant relationship among the variables when in fact there is none. The classical example 
includes a very high, positive correlation—referred to as a nonsense correlation in Yule 
(1926)—between standardized mortality per 1,000 persons in England and Wales and the 
proportion of Church of England marriages per 1,000 of all marriages. In empirical analysis 
the problem of spurious regression is expected to arise very often, see Granger (1966), who 
showed that economic variables typically are non-stationary. 
In Health Economics the empirical research greatly benefited from new developments in time 
series analysis. For example, investigating the relationship between health care expenditure 
and GDP one can distinguish between the following two stages (see Hartwig (2008) for an 
overview). The first stage is characterized mostly by cross-sectional studies (e.g., see 
Kleinman (1974), Newhouse (1977, 1987), Cullis and West (1979), Leu (1986), Parkin et al. 
(1987), Culyer (1990), Milne and Molana (1991), Getzen and Poullier (1991), Gertram and 
Jönsson (1991a,b)) such that the issue of spurious correlation could be avoided.  
At the second stage the time series properties of the variables in question received more 
attention. The analyses include application of tests for the presence of unit roots and testing 
for cointegration between health care expenditure and GDP (e.g., see Murthy and Ukpolo 
(1994), Hansen and King (1996), Blomquist and Carter (1997), McCoskey and Selden 
(1998), Roberts (1999), and Gerdtham and Löthgren (2000)). Jewell et al. (2003) and 
Carrion-i-Silvestre (2005) extend the literature by addressing time series properties of the 
modelled variables allowing for structural breaks. See also an overview of the relevant 
literature as well as a brief description of unit root and cointegration methodology in 
Gerdtham and Jönsson (2000).  
Nevertheless, the need for appropriate modelling of relationships involving time series 
variables so far has not been fully acknowledged in applied health economics. One example 
is the recent study of Lichtenberg (2004), which relates longevity in the United States to 
pharmaceutical innovation and public health care expenditure. The results of Lichtenberg 
(2004) suggest that recent increases in U.S. life expectancy are attributable to pharmaceutical 
innovation and public health care expenditure (HCEP) rather than health care expenditure 
(HCE) in general and non-medical determinants such as real GDP per capita which are found 
to be insignificant. 
A potential problem with the conclusions reached in Lichtenberg (2004) is that the issue of 
spurious regression has not been addressed in a systematic way. This failure is important 
because it entails the risk of linking health status to medical (and non-medical) inputs when 
no links exist. Given the fact that the conclusions of Lichtenberg (2004) could have far-
reaching consequences for conducting health policy in the United States, one has to verify his 
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results using a methodology that explicitly takes into account the issue of spurious 
correlation. 
Contributing to the literature, we replicate the study of Lichtenberg (2004) using an 
appropriate econometric methodology that is robust against the spurious regression problem. 
To this end, we use the bounds testing procedure suggested by Pesaran, Shin, and Smith 
(2001), which has a number of advantages over other methods as outlined below in Section 2. 
We apply it to the Lichtenberg (2004) data in order to sort out whether the results reported 
therein are due to spurious correlation or reflect a genuine relationship between the variables 
in question.  
The rest of the paper proceeds as follows. In Section 2 the bounds testing procedure of 
Pesaran et al. (2001) is described in detail. In Section 3 the results are presented and the final 
section concludes. 
2. Method 
In order to resolve the spurious correlation problem, the bounds testing procedure developed 
by Pesaran et al. (2001) will be presented in the following. This choice can be justified based 
on the following considerations. First, the bounds testing approach has broad applicability 
since the regressors can be of different and/or mixed order of integration, e.g., the variables 
can be either integrated of order one [technically, I(1)], of order zero [I(0)], or mutually 
cointegrated. This is a great advantage since the unit root tests regarding the order of 
integration of the relevant variables yield inconclusive results (as discussed in Lichtenberg, 
2004). Second, the procedure is based on the unrestricted error correction model, which 
permits joint estimation of long and short-run effects. As pointed out in Banerjee et al. (1993, 
1998), joint estimation has better statistical properties than the two-step Engle-Granger 
procedure that pushes the short-run dynamics into the error term. Third, as discussed in 
Narayan (2005), the bounds testing procedure performs rather well in small samples like the 
one employed in Lichtenberg (2004).  In small samples, application of the more popular Full 
Information Maximum Likelihood method (Johansen, 1995) is problematic. 
To implement the bounds testing procedure in the present context, one assumes that life 
expectancy (LE), new molecular entities (NME, a measure of pharmaceutical innovation), 
and public health care expenditures per capita (HCEP) are related according to a vector 
autoregressive (VAR) model. Dropping real GDP and health care expenditures in general that 
were found insignificant by Lichtenberg (2004) and also by us, the VAR model that can be 
reduced to the following conditional error correction model (ECM), 
1
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Here, p is the lag length of the underlying VAR model. The lagged values of LE, NME and 
HCEP (are in logs) form a long-run relationship in levels. The deterministic terms such as a 
constant, a linear trend, and dummy variables are denoted by DTt. The short-run dynamics is 
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captured by means of lagged values of LEt and current and lagged values of NMEt  and 
HCEPt. The data span the time period from 1960 to 2001. The conditional long-run 
elasticities of life expectancy with respect to MNE and HCEP are given by –1/ 0 and –2/ 
0, respectively (Banerjee et al., 1998). 
The bounds testing procedure uses the conventional F test for testing the null hypothesis 0H : 
1=2=0. Note that this statistic has a non-standard distribution which depends upon (i) the 
order of integration of the regressors; (ii) the number of regressors; (iii) the set of 
deterministic terms included in the model; and (iv) sample size.  Pesaran et al. (2001) provide 
the set of asymptotic critical values, generated from 1,000 bootstraps. However, given a small 
sample size (41 observations in the present case), these values are likely to be inappropriate. 
Therefore, the critical values reported in Narayan (1995) for small sample sizes are used in 
the following. 
There are two sets of critical values. The first set gives the lower bound, applicable when all 
regressors are I(0). The second gives the upper bound, applicable when all regressors are I(1). 
If the calculated F statistic falls below the lower bound, the null hypothesis of no relationship 
in levels cannot be rejected. Conversely, if the F statistic exceeds the upper bound, the null 
hypothesis of a level relationship can be accepted. Both rules hold irrespective of the order of 
integration of the regressors. Finally, if the F statistic falls within the critical bounds, the 
order of integration of the variables must be established in order to obtain conclusive 
inference. 
3. Test results 
Table I presents the results of the lag order p selection procedure for equation (1). The 
information criteria (Akaike, AIC and Schwarz, SIC) as well as the Langrange Multiplier 
statistic testing for remaining autocorrelation of order 1 and up to 4 in regression residuals are 
reported. As a robustness check, equation (1) is estimated without and with a linear trend. 
Table I: Lag order selection 
          
 Without deterministic trends  With deterministic trends 
P AIC SIC AR(1) AR(4)  AIC SIC AR(1) AR(4) 
          
1 -9.377 -9.078 0.158 0.448  -9.340 -8.999 0.190 0.480 
2 -9.382 -8.956 0.357 0.533  -9.344 -8.875 0.370 0.540 
3 -9.278 -8.723 0.818 0.469  -9.230 -8.633 0.792 0.459 
          
Notes: p is the lag order of the underlying VAR model for the conditional ECM of 
equation (1). Bold entries indicate the preferred lag order. AIC and SIC are the Akaike 
and Schwarz Information Criteria, respectively. AR(1) and AR(4) are the LM test 
statistics for testing for residual autocorrelation of orders up to 1 and 4, respectively. 
 
When no deterministic trend is included, the AIC selects p=2 whereas the SIC selects p=1. In 
both cases, there is no evidence of remaining autocorrelation in the regression residuals. 
Adding a linear deterministic term does not change these conclusions. Given the evidence of 
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no residual autocorrelation regardless of the value of p and a rather small number of 
observations, the parsimonious model with p=1 is preferred. Next, it seems that inclusion of a 
linear deterministic trend is not supported either by AIC or SIC, since both statistics take on a 
higher value (indicating better fit) without a linear trend. Therefore, the model with p=1 and 
without a linear trend in Table 1 will be used for the bounds testing procedure. Nevertheless, 
the results with a trend included will also be reported to provide some sensitivity analysis. 
From the five cases distinguished by Pesaran et al. (2001), the preliminary results reported 
above calls for retaining the following three,  
Case III: unrestricted constant and no trend;  
Case IV: unrestricted constant and restricted trend;  
Case V: unrestricted constant and unrestricted trend.  
Table II: F-test statistics for testing the existence of a levels relationship 
    
P FIII FIV FV 
    
1 10.437*** 10.556*** 10.385*** 
2 7.607*** 7.839*** 7.565** 
    
Notes:  FIII, FIV, and FV are the F-test statistics that correspond to the three cases 
mentioned in Pesaran et al. (2001): Case III – an unrestricted constant and no linear 
deterministic trend; Case IV – unrestricted constant and restricted linear deterministic 
trend; Case V –  unrestricted constant and unrestricted linear deterministic trend. 
Symbols ‘***’ and ‘**’ indicate that the F-statistic exceeds the upper bound 
corresponding to the 1% and 5% significance levels, respectively, as reported in 
Narayan (2005) for T = 40. 
 
The corresponding F test statistics are denoted as FIII, FIV, and FV  in Table 2. They exceed 
the critical upper bound (1 percent significance level) in all cases except for FV, which 
exceeds the critical upper bound at the 5 percent significance level for p=2. This finding 
indicates that the null hypothesis of no relationship in levels can be rejected. Thus, longevity, 
the number of new molecular entities, and public per capita health expenditure are related. 
This finding is robust both to lag length and the inclusion of a deterministic trend.  
Next, one can capitalize on the existence of this relationship for the modelling of the health 
production function. The objective is to find the most parsimonious model passing the 
standard diagnostic tests.  The implied values of the long-run impact coefficients of that 
model can then be compared with those reported by Lichtenberg (2004). The equation 
obtained reads (standard errors in parentheses, error probabilities in brackets): 
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-1 -1
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            (0.140)   (0.0011)                (0.037)              (0.0016)       
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            (0.00
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HCEP D
∆ ∆
19)                         (0.0022)    
                              (2)      
R2 = 0.566, F(5,35) =  9.129 [0.000], T =  41 
AR 1-2 test: F(2,33)  =   1.651 [0.207]  
ARCH 1-1 test:     F(1,33)   = 0.140 [0.710]  
Normality test: )2(2χ
   
= 0.241 [0.886]  
Heteroskedasticity test: F(9,25)     = 1.218 [0.329]  
Heteroskedasticity-X test:   F(15,19)  = 1.135 [0.392]  
RESET test:                        F(1,34)   = 0.683 [0.415]  
 
All coefficients are estimated with a high degree of precision. The model passes all standard 
specification tests, including tests of no residual autocorrelation, of no residual ARCH 
effects, of no residual heteroskedasticity, of residual normality, and of no functional form 
misspecification. These encouraging results are also supported by the close match between 
actual and the fitted values displayed in the top panel of Figure 1.  The estimated regression 
residuals show no sign of misspecification (middle panel).1 Finally, the autocorrelation 
function (bottom panel) takes on rather small values that moreover change signs for lags 
ranging from 1 to 5 years.  
Finally, the results of the Chow tests for recursive stability (Chow, 1960) are shown in Figure 
2.  The values of the 1-step, breakpoint, and forecast Chow test statistics are compared to 
their respective 5% critical values (Doornik and Hendry, 2001).  None of the tests show any 
sign of model instability. 
According to equation (2), the long-run elasticities of life expectancy with respect to 
pharmaceutical innovation and public health expenditure are 0.0408 and 0.0432, respectively.  
These values are close to those reported in Lichtenberg (2004, Table 3), i.e. 0.0390 and 
0.0434. In sum, the estimates reported by Lichtenberg (2004) cannot be said to result from 
spurious correlation; to the contrary, they very likely reflect an effective relationship between 
life expectancy on the one hand and, pharmaceutical innovation and public health care 
expenditure on the other in the United States.  
                                                 
1
 In Equation (2), D93 denotes a dummy that is equal to one in 1993 and zero otherwise. The dummy in 1993 accounts for a decrease in life-
expectancy in that year that cannot be explained by developments neither in pharmaceutical innovation nor in public health care 
expenditures. According to Kranczer (1994), “In 1993, a decrease in life expectation was primarily brought about by the considerable rise in 
the absolute number of deaths and the corresponding increase in mortality rates. Indications are that mortality increased from all major 
forms of death as well as from AIDS. It is estimated that there were 2,260,000 deaths in 1993 compared with the provisional count of 
2,177,000 in 1992 and the final figure of 2,169,518 in 1991.” 
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Figure 1: Actual and fitted values (the upper panel); Regression residuals (the middle 
panel); Autocorrelation function of regression residuals (bottom panel). 
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Figure 2: Recursive stability 1-step, breakpoint, and forecast Chow test statistics scaled 
by their respective 5% critical values. 
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4. Concluding remarks 
As already noted by Gerdtham and Jönsson (2000), health economists until recently have 
been paying rather little attention to the fact that some of their data are of the time series type. 
However, there are modern econometric techniques for detecting the existence of a 
relationship between variables that can be integrated either of order one or zero, or mutually 
cointegrated. Applying these techniques to the paper by Lichtenberg (2004), this note finds 
that the null hypothesis of no relationship between life expectancy, pharmaceutical 
innovation, and public health care expenditure in the United States can be rejected.  
However, there are other recent works that might be subjected to a similar scrutiny. For 
example, Zweifel et al. (2005) employ panel data for revisiting the so-called Sisyphus 
syndrome (Zweifel and Ferrari, 2002), which involves a production function (HCE resulting 
in more elderly survivors) and a HCE function (where elderly survivors exert public pressure 
for more HCE). Other panel data applications that investigate the relation between life 
expectancy and health care spending include Crémieux et al. (1999), and Or (2001). More 
specifically, the findings by Peltzman (1987), Lichtenberg (1996), Moore and Newman 
(1993), Soumerai et al. (1994), and Crémieux et al. (2005), that pharmaceutical consumption 
contribute life expectancy could be checked using the testing procedures described in this 
note.   
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